Key Takeaway: GSK, a partner of Ionis, has received approval from Japan's Ministry of Health for Hibsago (bepirovirsen) as the first and only functional cure for chronic hepatitis B. This landmark decision marks a significant milestone in the treatment landscape for hepatitis B, offering new hope for patients in Japan. The approval underscores the successful collaboration between Ionis and GSK.
Price reaction · baseline $59.74 (2026-08-21 close) · hit pre-market · clean, no other IONS news in the window
day 0 close · peak
+3.9%
Market Sentiment Analysis
POSITIVE FACTORS
Hibsago is approved as the first functional cure for chronic hepatitis B in Japan.
The approval represents a significant advancement in hepatitis B treatment.
This achievement highlights the collaboration between Ionis and GSK.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+3%
120-day peak, hindsight
Typical move
3.7%
average across 15 past catalysts
Lead asset
ISIS 416858
Phase 2 · End-stage Renal Disease (ESRD)
Full Press Release Details
Ionis partner GSK announces Hibsago (bepirovirsen) approved in Japan as first and only functional cure for chronic hepatitis B August 24, 2026 – Ionis partner GSK today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Hibsago (bepirovirsen) as a functional cure for
Frequently Asked Questions
What is Hibsago?
Hibsago (bepirovirsen) is a treatment approved as a functional cure for chronic hepatitis B.
Who announced the approval of Hibsago?
The approval of Hibsago was announced by GSK, a partner of Ionis.
When was Hibsago approved in Japan?
Hibsago was approved in Japan on August 24, 2026.
What does the approval of Hibsago signify?
It signifies a significant advancement in the treatment of chronic hepatitis B.